latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
Published 5 years ago • 506 plays • Length 3:13Download video MP4
Download video MP3
Similar videos
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
3:52
keynote 10: pembrolizumab vs docetaxel for nsclc
-
6:32
latest results from keynote-181: pembrolizumab versus chemotherapy as a second-line therapy for ...
-
6:32
keynote trials show pembrolizumab benefited patients with advanced small cell lung cancer
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
4:50
comment: reasonable to conclude that pembrolizumab is non-inferior to chemotherapy
-
11:05
keynote-042: should pembrolizumab replace chemo for broader population with adv. nsclc? (bmic-038)
-
2:30
association between ttmb and clinical outcomes with pembrolizumab alone in pd-l1-positive advanc...
-
5:16
keynote-001: five year data from the phase ib trial studying pembrolizumab as treatment for ansclc
-
3:32
keynote-028 and keynote-158: pembrolizumab as treatment for advanced sclc after two or more line...
-
3:44
pembrolizumab plus platinum-based chemotherapy for metastatic nsclc
-
5:42
keynote-189: chemotherapy and pembrolizumab in mnsclc
-
6:21
pembrolizumab plus trastuzumab and chemotherapy for her2 metastatic gastric or gastroesophageal...
-
4:39
chemotherapy pembrolizumab: a new standard of care?
-
3:02
updates from keynote 57: pembrolizumab for patients with bladder cancer
-
3:14
keynote-062 study: pembrolizumab as treatment for advanced gastroesophageal junction and gastric...
-
4:12
nondriver nsclc: adding pembrolizumab to platinum-based chemotherapy
-
3:10
pembrolizumab new option for firstline treatment of advanced lung cancer with high pdl-1 expression